Xiaoyan Ge

Dr. Xiaoyan Ge


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
KCKai Cui
Kai Cui
WMWeihan Meng
Weihan Meng
ZLZhiqiang Li
Zhiqiang Li
XZXinning Zeng
Xinning Zeng
XLXiaozhe Li
Xiaozhe Li
XGXiaoyan Ge
Xiaoyan Ge
Background: Little is known about the association of longitudinal dynamics between cognitive function and frailty in Chinese older adults. The temporal sequences between cognitive function and frailty remains unclear. Our study investigates this directionality association using longitudinal data. Methods: Latent growth and multivariate latent growth models were employed to examine dynamics of cognition and frailty and their association among 2824 older adults in China. Cross-lagged panel analyses were used to assess the temporal sequences between frailty and cognition. The relation between cognitive domains and frailty was also examined using aforementioned methods. Results: Cognitive function was negatively associated with frailty status. Higher initial level of cognition indicated lower baseline level (β=-0.175, P < 0.001) and change rate (β=-0.041, P = 0.002) of frailty. We observed a reciprocal association between frailty and cognitive function rather than a unidirectional causal relationship. The initial cognitive performance for all components were negatively associated with baseline (β ranged between − 0.098 to -0.023) and change rate (β ranged between − 0.007 to -0.024) of frail status. No consistent associations between change rate of cognitive components and either initial level or change rate of frailty were detected. Conclusions: Our study detected a reciprocal association between cognition and frailty rather than a unidirectional causal relationship. Our results also revealed different connections between cognitive performance and frailty across diverse cognitive domains.

2 February 2025 in Age and Ageing
Verified
Journal Article
Closed access
KCKai Cui
Kai Cui
RZRonghui Zhao
Ronghui Zhao
NDNing Ding
Ning Ding
XXXiaonuo Xu
Xiaonuo Xu
WGWeiqi Gu
Weiqi Gu
XGXiaoyan Ge
Xiaoyan Ge
Background: The course of decline of global cognitive function is heterogeneous, with patterns varying among individuals. The influence of depression, functional limitations and multimorbidity on patterns of decline of global cognitive function among community-dwelling older adults remains unknown. This study examines the relationship between these health conditions and the course of decline of global cognitive function. Methods: A prospective cohort of 4032 participants aged ≥60 years at baseline was constructed using the Health and Retirement Study (2006–20), through surveys every 2 years. Information on depression, functional limitations and multimorbidity was collected from 2006 to 2012. Data on cognitive function were collected between 2012 and 2020. Latent class trajectory models were used to identify the latent trajectories. Multinomial logistic regression models were employed to analyse the association between the latent trajectories and cognitive function. Results: Different trajectories were identified for depression (low-stable, decline-rise and rise-decline), activities of daily living (ADLs; low-stable, decline-rise and rise-decline), instrumental activities of daily living (IADLs; low-stable and rise), and multimorbidity (stable and rise). Three trajectories of cognitive decline were identified: high stable, modest and later steep. The trajectories of depression (for decline-rise: OR: 1.47, 95% CI: 1.11–1.95; for rise-decline: OR: 1.72, 95% CI: 1.24–2.38) and multimorbidity (OR: 1.63, 95% CI: 1.08–2.46) increased the risk of cognitive decline. Conclusion: The trajectories of depression and multimorbidity affect cognitive decline patterns. Longitudinal surveillance of health conditions can be used to identify different patterns of cognitive decline and predict faster cognitive decline.

17 September 2023 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
XGXiaoyan Ge
Xiaoyan Ge
KCKai Cui
Kai Cui
YQYao Qin
Yao Qin
DCDurong Chen
Durong Chen
HHHongjuan Han
Hongjuan Han
HYHongmei Yu
Hongmei Yu

22 July 2022 in Medicine
Verified
Journal Article
Open access
XGXiaoyan Ge
Xiaoyan Ge
WMWeihan Meng
Weihan Meng
WWWenbo Wang
Wenbo Wang
HMHonglin Ma
Honglin Ma
SZSiqi Zhao
Siqi Zhao
KCKai Cui
Kai Cui
The primary plasma cell leukemia (pPCL) is a rare but aggressive variant of multiple myeloma (MM). Few studies have focused on the differences in the causes of death between pPCL and MM. This study aimed to compare and evaluate the causes of death of patients with pPCL and MM. The data were collected from the Surveillance Epidemiology, and End Results (SEER) database. The demographic characteristics, survival, and causes of death in pPCL and MM patients were evaluated and compared. The competing risk regression model was performed to predict the cause of death. Between 1975 and 2009, the overall mortality rate was 96.13% and 88.71% for pPCL and MM, and the median survival was 9 and 26 months, respectively. In pPCL, leukemia caused 45.05% of the deaths, followed by myeloma (38.83%). In MM, myeloma was the leading cause of death, accounting for 74.89% of the deaths. Older age at diagnosis was a risk factor for dying of leukemia in pPCL patients (HR = 1.49, 95% CI: 1.16–1.91), while older age at death was associated with reduced risk (HR = 0.67, 95% CI: 0.52–0.86). Although the survival of pPCL patients increased with time periods of diagnosis since 1975 to 2009, the risk of dying of leukemia increased with the periods. For MM, most of the demographic characteristics were found to have independently predicting influence on the cause of death. Patients with pPCL and MM had distinct causes of death. Leukemia was the leading and the most serious cause of death in pPCL patients. The demographic factors could not predict the causes of death in pPCL. More large-scale and multi-center studies are needed to evaluate the effect of novel agents in pPCL patients, especially for patients who have progressed to leukemia.